New combo therapy aims to boost immune attack on head and neck tumors before surgery
NCT ID NCT06159621
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This early-phase study tests two drugs (LVGN7409 and LVGN3616 or nivolumab) given together before surgery in 27 adults with HPV-negative head and neck cancer. The goal is to see if the combination is safe and can increase immune cell activity in the tumor. Participants will have their tumors removed as planned, and researchers will compare immune markers before and after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.